Pulmonary Fibrosis Research Enhancement Act
Latest action (12 Jul 2011): Introduced
What this bill does
Pulmonary fibrosis (PF) is a progressive lung disease with no FDA-approved cure and low public awareness, despite affecting several hundred thousand Americans. H.R. 2505 would direct federal health agencies to expand research, tracking, and public education efforts related to PF. Specifically, it would require the CDC to establish a National Pulmonary Fibrosis Advisory Board, composed of representatives from agencies such as NIH, the VA, and the Agency for Toxic Substances and Disease Registry, along with patients, clinicians, and researchers. This board would advise on creating a National PF Registry to collect data on incidence, causes, and demographics of PF cases, coordinated with existing state and federal databases. The bill also calls for a National Pulmonary Fibrosis Education and Awareness Plan to improve patient and physician education, and it encourages the relevant NIH institute to expand PF-related research.
The bill primarily affects federal public health agencies (CDC, NIH, VA), which would take on new administrative duties, as well as PF patients, their families, clinicians, and researchers who would benefit from improved data collection, coordination, and awareness efforts.
H.R. 2505 was introduced on July 12, 2011, by Rep. Erik Paulsen with bipartisan co-sponsors, and referred to the House Committee on Energy and Commerce. According to the official record, it did not receive a vote and saw no further action before the end of that Congress, meaning it did not become law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Pulmonary Fibrosis Research Enhancement Act - Amends the Public Health Service Act to require the Director of the Centers for Disease Control and Prevention (CDC) to: (1) establish the National Pulmonary Fibrosis Advisory Board, (2) develop a system to collect data on pulmonary fibrosis and other interstitial lung diseases, and (3) establish the National PF Registry.
Requires the Secretary of Health and Human Services (HHS), in developing the Registry, to: (1) expand and coordinate existing data and surveillance systems, surveys, registries, and other federal public health and environmental infrastructure; and (2) provide for research access to pulmonary fibrosis data.
Directs the Secretary to ensure that epidemiological and other types of information are made available to the National Institutes of Health (NIH) and the Department of Veterans Affairs (VA).
Requires the Director of CDC to prepare the National Pulmonary Fibrosis Education and Awareness Plan, which shall: (1) focus on strategies to increase public education and awareness of pulmonary fibrosis, (2) address the need for new physician education strategies to improve diagnosis and treatment standards, and (3) assess and monitor the costs of pulmonary fibrosis and its burden on patients and families.
Encourages the Director of the National Heart, Lung, and Blood Institute to expand, intensify, and coordinate Institute pulmonary fibrosis research activities.
Common questions
- What does H.R. 2505 do?
- Pulmonary fibrosis (PF) is a progressive lung disease with no FDA-approved cure and low public awareness, despite affecting several hundred thousand Americans. H.R. 2505 would direct federal health agencies to expand research, tracking, and public education efforts related to PF. Specifically, it would require the CDC to establish a National Pulmonary Fibrosis Advisory Board, composed of representatives from agencies such as NIH, the VA, and the Agency for Toxic Substances and Disease Registry, along with patients, clinicians, and researchers. This board would advise on creating a National PF Registry to collect data on incidence, causes, and demographics of PF cases, coordinated with existing state and federal databases. The bill also calls for a National Pulmonary Fibrosis Education and Awareness Plan to improve patient and physician education, and it encourages the relevant NIH institute to expand PF-related research. The bill primarily affects federal public health agencies (CDC, NIH, VA), which would take on new administrative duties, as well as PF patients, their families, clinicians, and researchers who would benefit from improved data collection, coordination, and awareness efforts. H.R. 2505 was introduced on July 12, 2011, by Rep. Erik Paulsen with bipartisan co-sponsors, and referred to the House Committee on Energy and Commerce. According to the official record, it did not receive a vote and saw no further action before the end of that Congress, meaning it did not become law.
- Has H.R. 2505 become law?
- Not yet. As of 12 Jul 2011, H.R. 2505 is introduced.
- Who sponsored H.R. 2505?
- H.R. 2505 was sponsored by Rep. Erik Paulsen [R-MN3, 2009-2018] (Republican-MN), with 77 cosponsors.
- What's the latest action on H.R. 2505?
- Introduced (12 Jul 2011).
Related bills in Health
Expressing support for the designation of September 22, 2026, as “National Hispanic Nurses Day” and recognizing the National Association of Hispanic Nurses as the leading organization representing and advocating for Hispanic nurses.
Recognizing the importance of protecting continuous Medicaid coverage for individuals undergoing active cancer treatment.
Wildland Firefighter Health and Safety Act
Expressing support for the designation of the third week of September as “Fungal Disease Awareness Week” and encouraging efforts to improve awareness, diagnosis, treatment, surveillance, and prevention of fungal diseases in the United States.
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.